aGVHD	acute Graft versus Host Disease
ALLO-SCT	allogeneic stem cell transplant
ASCT	autologous stem cell transplant
ATG	Anti Thymocyte Globuline
BCR	B-cell receptor
BR	Bendamustine—Rituximab
BSBMT	British Society of Blood and Marrow Transplantation
BTK	Bruton’s Tyrosine Kinase
CAR T	Chimeric Antigen Receptor T cell therapies
cGVHD	chronic Graft versus Host Disease
CIBMTR	Center for International Blood and Marrow Transplant Research
CLL	Chronic Lymphocytic Leukemia
c-MIPI	combined MIPI
CMV	cytomegalovirus
CR	complete response
CRS	Cytokine release syndrome
DLBCL	diffuse large B cell lymphoma
DLI	donor-lymphocyte infusion
DOR	duration of response
DSA	donor-specific antibodies
EBMT	European Society for Bone Marrow & Transplantation
EFS	event free survival
ESMO	European Society for Medical Oncology
FDG-PET	fluorodeoxyglucose—Positron Emission Tomography
FIL	Fondazione Italiana Linfomi
GVL	graft versus lymphoma
HCT	hematopoietic cell transplant
HCT-CI	hematopoietic cell transplantation comorbidity Index
HD ARA-C	High dose Cytarabine
HLA	Human Leukocyte Antigen
IBMTR	International Bone Marrow Transplant Registry
iBTK	BTK inhibitors
MCL	Mantle cell lymphoma
MIPI	Mantle cell International Prognostic index
miRNA	microRNA
MRD	minimal residual disease
MTX	methotrexate
MUD	matched unrelated donor
NHL	Non-Hodgkin Lymphoma
NMA	nonmyeloablative conditioning regimen
NRM	non-relapse mortality
ORR	overall response rate
OS	overall survival
PFS	progression free survival
POD	progression of disease
PR	partial response
R-BAC	Rituximab + Bendamustine + Cytarabine
R- CHOP	Rituximab + Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
R-DHAP	Rituximab -Dexamethasone—high dose Cytarabine—Cisplatin
R- Hyper CVAD	Rituximab + Cyclophosphamide, Vincristine, Doxorubicin (Adriamycin), and Dexamethasone
RIC-ALLO SCT	reduced intensity conditioning—allogeneic stem cell transplant
RIC	reduced intensity conditioning
R/R	relapsed/refractory
TBI	total body irradiation
TRM	transplant related mortality
URD	unrelated donor
VR- CAP	bortezomib + rituximab + cyclophosphamide + doxorubicin and prednisone